XML 51 R42.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Commitments and Contingencies - Additional Information (Details) - USD ($) $ in Millions | 1 Months Ended | 9 Months Ended
--- | --- | ---
Aug. 31, 2020 | Sep. 30, 2022
Commitments And Contingencies [Line Items] |  |
Lease arrangement, contractual expiration period, beginning year |  | 2022
Lease arrangement, contractual expiration period, ending year |  | 2033
Lessee, operating lease, existence of option to extend [true false] |  | true
Lessee, operating lease, option to extend |  | These leases require monthly lease payments that may be subject to annual increases throughout the lease term. Certain lease agreements also provide the Company with the option to renew for additional periods ranging from one to five years.
GSKTSL | Wuxi Biologics Letter Agreement Assignment And master Service Agreements | Antibody Program |  |
Commitments And Contingencies [Line Items] |  |
Percentage of development costs | 72.50% |
GSK | Wuxi Biologics Letter Agreement Assignment And master Service Agreements | Antibody Program |  |
Commitments And Contingencies [Line Items] |  |
Percentage of development costs responsible by GSK | 27.50% |
CDMO |  |
Commitments And Contingencies [Line Items] |  |
Payment committed for manufacturing capacity |  | $ 7.2
Pre pay for raw materials |  | 5.0
Non-refundable prepayment for raw materials |  | $ 5.0
Minimum [Member] |  |
Commitments And Contingencies [Line Items] |  |
Lessee, operating lease, renewal term |  | 1 year
Maximum |  |
Commitments And Contingencies [Line Items] |  |
Lessee, operating lease, renewal term |  | 5 years

X
- Definition Indicates (true false) whether lessee has option to extend operating lease. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 50 -Paragraph 3 -Subparagraph (a)(3) -URI https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980 + Details
Name: | us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend
Namespace Prefix: | us-gaap_
Data Type: | xbrli:booleanItemType
Balance Type: | na
Period Type: | duration

X
- Definition Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 50 -Paragraph 3 -Subparagraph (a)(3) -URI https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980 + Details
Name: | us-gaap_LesseeOperatingLeaseOptionToExtend
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 842 -SubTopic 20 -Section 50 -Paragraph 3 -Subparagraph (a)(3) -URI https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980 + Details
Name: | us-gaap_LesseeOperatingLeaseRenewalTerm
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | instant

X
- Definition Commitments and contingencies. + References No definition available. + Details
Name: | vir_CommitmentsAndContingenciesLineItems
Namespace Prefix: | vir_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Lease arrangement, contractual expiration beginning year. + References No definition available. + Details
Name: | vir_LeaseArrangementContractualExpirationBeginningYear
Namespace Prefix: | vir_
Data Type: | xbrli:gYearItemType
Balance Type: | na
Period Type: | duration

X
- Definition Lease arrangement, contractual expiration ending year. + References No definition available. + Details
Name: | vir_LeaseArrangementContractualExpirationEndingYear
Namespace Prefix: | vir_
Data Type: | xbrli:gYearItemType
Balance Type: | na
Period Type: | duration

X
- Definition Payment Commitment Manufacturing Capacity + References No definition available. + Details
Name: | vir_PaymentCommitmentManufacturingCapacity
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Payment Commitment Raw Materials + References No definition available. + Details
Name: | vir_PaymentCommitmentRawMaterials
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Percentage of development costs that the Company is responsible for. + References No definition available. + Details
Name: | vir_PercentageOfDevelopmentCostsResponsibleByCompany
Namespace Prefix: | vir_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of development costs that GSK is responsible for. + References No definition available. + Details
Name: | vir_PercentageOfDevelopmentCostsResponsibleByGsk
Namespace Prefix: | vir_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Prepayment Raw Materials + References No definition available. + Details
Name: | vir_PrepaymentRawMaterials
Namespace Prefix: | vir_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=vir_GlaxoSmithKlineTradingServiceLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=vir_WuxiBiologicsLetterAgreementAssignmentAndMasterServiceAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=vir_AntibodyProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=vir_ClinicalDevelopmentAndManufacturingOrganizationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |